End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
862 USD | 0.00% |
|
0.00% | 0.00% |
06-21 | Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar | RE |
06-21 | Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 66.11 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 796B | - | ||
+41.51% | 628B | B | ||
-5.10% | 358B | C+ | ||
+19.90% | 331B | B- | ||
+9.95% | 301B | C+ | ||
+17.66% | 244B | B+ | ||
+3.39% | 228B | A+ | ||
+10.75% | 214B | B- | ||
+6.99% | 165B | C+ | ||
-3.65% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LLY Stock
- Stock
- Ratings Eli Lilly and Company